News
NVS
94.41
+0.95%
0.89
MorphoSys AG Form SC TO-T/Amended Shows Novartis BidCo AG Bought 2,023,370 Shares Of Common Stock Or About A 5.36% Stake; Highest Price Paid Was €67.95 Per Share
On 11 April 2024, Novartis BidCo, Basel, Switzerland, has published the takeover offer for MorphoSys AG. The highest price paid was EUR 67.95 per Morphosys Share. The acceptance period of the offer will expire on 13 May 2024. The Bidder acquired 2,023,370 MorphoSy Shares.
Benzinga · 8h ago
Novartis Gets Priority Review for Kidney Disease Treatment
Novartis says it received priority review for its potential treatment for a rare kidney disease. The company's treatment is being evaluated in a Phase 3 trial. The drug company says its submission to the FDA for potential accelerated approval has been accepted. Fabhalta received FDA approval in December 2023 to treat a rare blood disorder.
Dow Jones · 10h ago
NEW NOVARTIS FABHALTA® (IPTACOPAN) DATA SHOW CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT PROTEINURIA REDUCTION OF 38.3% VERSUS PLACEBO FOR PATIENTS WITH IGA NEPHROPATHY (IGAN)
Reuters · 10h ago
Weekly Report: what happened at NVS last week (0408-0412)?
Weekly Report · 19h ago
UPDATE 1-China c.bank keeps policy rate unchanged, drains cash from banking system
China's central bank leaves key policy interest rate unchanged, drains cash from banking system. The central bank is expected to maintain currency stability and push back on market expectations of a rate cut. The bank drained some cash from the banking system through the bond instrument. Cooling inflation, slowing credit expansion and shrinking exports in March all point to more stimulus.
Reuters · 1d ago
AbbVie keeps Humira market share near 100% despite biosimilars: report
Healthcare AbbVie keeps Humira market share near 100% despite biosimilars: report. Humira is the world's bestselling drug for the 10th year in a row. Amgen launched the first biosimilar version of the arthritis drug in the U.S. Last year.
Seeking Alpha · 2d ago
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
NASDAQ · 3d ago
China c.bank set to leave policy rate unchanged, drain some liquidity
China's central bank is set to leave a key policy rate unchanged when rolling over maturing medium-term loans on Monday. Majority of respondents expect some liquidity to be drained via the bond instrument. Market watchers believe Beijing will continue to prioritise the stability of the yuan.
Reuters · 3d ago
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
Arvinas and Novartis partnering on prostate cancer protein degrader is a win-win situation for both parties. Arvinas's shares are up more than 75% since November 2023. The biotech's lead asset, vepdegestrant, is being developed in partnership with Pfizer for breast cancer studies.
Seeking Alpha · 4d ago
What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences
Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion. Vertex is gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications. The acquisition also includes Alpine's protein engineering and autoimmune expertise. The deal brings no revenues until at least 2027 and will produce modest upside for Vertex.
Seeking Alpha · 4d ago
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Vertex Pharmaceuticals Incorporated agreed to acquire Alpine Immune Sciences Inc for $65 per share or approximately $4.9 billion in cash. Evercore notes the deal as a surprise move for Vertex. The company has been criticized for its capital allocation in the past.
Benzinga · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Rent the Runway, Lumen Technologies, Enliven Therapeutics
The Dow Jones Industrial Average was up 0.02% on Thursday. The benchmark S&P 500 and the Dow were muted as long-dated Treasury yields remained elevated. Rent the Runway, Lumen Technologies, Enliven Therapeutics were among the top stocks on the NYSE.
Reuters · 4d ago
Bausch wins US appeal to block Alvogen generic of diarrhea drug
Bausch Health wins US appeal to block Alvogen generic of diarrhea drug. Bausch's diarrhea treatment Xifaxan is approved to treat traveler's diarrhea and irritable bowel syndrome. A federal court ruled Alvogen's generic would infringe patents owned by Baus ch's Salix Pharmaceuticals.
Reuters · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
The benchmark S&P 500 and the Nasdaq gained on Thursday. Producer prices data soothed investor jitters about sticky inflation. The Dow Jones Industrial Average was down 0.36% in the morning. Constellation Brands, Nike, Rocket Lab and Domino's Pizza are among the stocks on the move.
Reuters · 4d ago
Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune
Vertex Pharmaceuticals announced a $4.9 billion deal to buy Alpine Immune Sciences. The company is developing a drug to treat a rare kidney disease. Vertex is known for its treatment of cystic fibrosis. The deal is a big bet on the company's potential to diversify its business.
Barron‘s · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Devon Energy, Arvinas
DoorDash, Devon Energy, Arvinas among top Nasdaq percentage gainers. Softer-than-anticipated producer prices data soothed investor fears about sticky inflation. Dow e-minis were up 0.08% in premarket trading. The Nasdaq eyed a higher open on Thursday.
Reuters · 4d ago
Vertex Pharma upgraded at Evercore on Alpine Immune deal
Vertex Pharmaceuticals to buy immunotherapy developer Alpine Immune Sciences for $4.9B. Evercore ISI upgraded Vertex to Outperform from In-Line on Thursday. The company's lead drug, povetacicept, could be the fourth to enter the immunotherapy market.
Seeking Alpha · 4d ago
UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion
Novartis taps Arvinas' cancer drug for up to $1 billion. Swiss drugmaker to gain access to U.S. Biotech firm's experimental prostate cancer drug. Shares of Connecticut-based arvinas rose more than 6% to $39 in premarket.
Reuters · 4d ago
UPDATE 1-Novartis licenses Arvinas' cancer drug for up to $1 billion
Novartis licenses Arvinas' cancer drug for up to $1 billion. Swiss drugmaker to gain access to experimental prostate cancer drug. Novartis has acquired global rights to develop and commercialize the drug, ARV-766. The drug is designed to target and degrade androgen receptors.
Reuters · 4d ago
More
Webull provides a variety of real-time NVS stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.